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(clinical T-stage, PSA and Gleason score) (AUC=0.685; 95%CI
0.630 to 0.736; p<0.0001) in the prediction of HRR.
Conclusion: The biopsy laterality as replacement of clinical T
stage contributes significantly to improve the value of NCCN
criteria for predicting subjects at HRR. 
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Introduction: The modified Clavien classification system has
been proposed to classify and grade complications in general
surgery and in the last years it is increasingly becoming a
popular method in urology. Aim of our study was to evaluate
the applicability of the modified Clavien classification system
(CCS). Patients and Methods: A consecutive series of patients
with primitive or recurrent bladder cancer treated with radical
cystectomy from April 2011 to August 2011 at eleven
academic centres in Europe were evaluated for complications
occurring up to the end of the first postoperative month.
Variables analyzed for each patient were: age, sex, asa score,
anticoagulation therapy, type of diversion, operation time,
preoperative hydronefrosis and BMI All complications were
prospectively recorded and classified according to the
modified CCS. Results were presented as complication rates
per grade. Chi-square and Kruskal Wallis tests and binary
logistic regression analysis were used for statistical analysis.
Results: 194 patients were prospectively enrolled. Mean age
was 57.8±12.7 years; mean BMI was 21.5±2.3 Kg/m2. Mean
bladder tumors size was 3.6±3.7 cm, mean number of bladder
lesions was 2±2. All patients underwent radical cystectomy.
Urinary diversion consisted in orthotopic neobladder in 44
patients (23%), ileal conduit in 89 patients (46%) and
ureterocutaneostomy in 61 patients (31%). Mean operative
time was 307±55 minutes. Mean hospital stay was 14.5±2.4
days. 185 complications were recorded in 123 patients.
Overall perioperative morbidity rate was 63%. Most of them
were not serious and were classified as Clavien type I (51
cases; 27.5%) or II (91 cases, 49%). Higher grade
complications were observed: Clavien type IIIa in 15 cases
(8%), IIIb in 18 cases (10%); IVa in 5 cases (3%), IVb in 2
cases (1%) and V in 3 cases (1.5%). Reoperation rate was 8%
(16 patients) for severe wound infection (4 patients), urinary
anastomosis leakage (4 patients) and ileal perforation or
occlusion (7 patients). Patients who underwent ileal conduit
urinary diversion presented a higher rate of CCS type I
complications (58%) when compared to other urinary
diversions (p=0.034). No significant association was found
between Age, BMI, ASA score, anti-coagulant treatment,
preoperative hydronephrosis, operative time, hospital stay and
CCS type I or ≥IIIb complications. Patients with CCS
complications type II and IIIa presented a significant longer
operative time and hospital stay in univariate and multivariate
analysis (p=0.01) (Table I). 
Table I. 
CCS type II CCS type IIIa
Yes No p Yes No P
Operative 
time (m) 338±108 294±111 0.000 379±126 309±109 0.031
Hospital 
stay (day) 16.8±5 12.9±5 0.000 20.4±9.3 14.29±6.2 0.021
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Discussion and Conclusion: The modified CCS represents
a practical and easily applicable tool that may help
urologists to classify the complications of radical
cystectomy and urinary diversion in a more objective and
detailed way. In our experience, using this CCS tool, radical
cystectomy is associated with a higher morbidity (63%), an
8% reoperation rate and a 1.5% of mortality. Ileal conduit
urinary diversion has a higher rate of type I complications.
Longer operative time and longer hospital stay are
associated with a higher risk of post operative
complications. 
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Introduction and Background: Active Surveillance is being
validated worldwide as an alternative to radical treatment
(surgery, radiotherapy and brachytherapy) for low risk prostate
cancer (PC). The aim of the study is to deal with the issue of
overdiagnosis resulting from PSA based opportunistic
screening, limit overtreating potentially indolent PC and avoid
therapy-induced side-effects. On these assumptions the SIUrO-
PRIAS-ITA project started enrolment in PRIAS (Prostate
Cancer Research International: Active Surveillance), the
international study on observational strategy in low risk prostate
cancer patients coordinated by the Erasmus University Medical
Center in Rotterdam, in December 2009. Patients and Methods:
Eligibility criteria for SIUrO-PRIAS-ITA: PSA 10 ng/ml,
Gleason Score 6 or Gleason 3+4 in over 69 yr men with <10%
positive cores, T1c or T2, PSA density 0.20, max 2 positive
bioptic cores (<10% positive cores in case of saturation biopsy),
biopsy samples according to the volume (8 for 0-40, 10 for 40-
60 and 12 for >60 ml), pathologic review of diagnostic biopsy.
At inclusion extensive information on the disease,
comorbidities, education, habits are collected and three
questionnaires administered: IPSS, IIEF and FACTP. Despite
the well known problems of misinterpretation of PSA values,
biopsy-induced sequelae and biopsy-resulting false
negative/positive reports, follow-up is still based on PSA every
3 months, clinical evaluation every 6 months, evaluation of PSA
doubling time (DT), rebiopsy at 12, 48 and 84 months and
possible extra biopsy (i.e. if PSA DT between 3 and 10 years).
Exit criteria: 3 yr PSA-DT, upsizing and/or upgrading at the
rebiopsy (Gleason 3+4 is accepted in over 69 yr men with
<10% positive cores). Results: From December 2009 to March
2012, 255 patients from 8 Italian centers entered the study;
mean age was 65.6 years (min 49 max 80); iPSA was <3 ng/mL
in 10.6 % patients, between 3 and 6 ng/ml in 54.5%, between 6
and 8 in 27% and >8 in 7.9%. 222 patients are still on protocol
with a median follow-up of 16.6 months (min 2 max 39); 33
discontinued active surveillance based on protocol or personal
decision. Reasons for discontinuation were upgrading at
rebiopsy in 4 cases, upsizing in 9 and upgrading plus upsizing
in 5, PSA DT <3 years in 2 cases, other causes in 2 cases (a
patient on follow-up for bladder cancer in a center not
participating in SIUrO-PRIAS-ITA was erroneously prescribed
hormonal therapy; a patient could not stop anticoagulants and
repeat biopsy), personal choice in 11 patients. Discussion and
Conclusion: Active Surveillance is proving an acceptable
alternative for patients with low risk PC, which might harbour
an indolent PC and thus overtreatment and treatment induced
toxicities can be avoided. Unfortunately, the definition of
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